Tevogen Bio's Dr. Neal Flomenberg and Dr. Dolores Grosso discuss the shift from chemotherapy to targeted therapies such as Jaypirca and highlight Tevogen’s antigen-specific T cell platform as a new frontier in cancer and infectious disease treatment.
- Survey: 30% Of Biopharmas Cite Cost, Productivity As Top Priorities
- Bringing CGT Home: Equipping Community Hospitals For The Next Frontier
- Import Product Specifications And Drug Registration Testing For China
- Navigating Regulatory Frameworks For Allogeneic CAR-NK Control Strategies
- Advancing Telomere Targeting Therapy For Non-Small Cell Lung Cancer
- Trust But Verify: Validating AI In Pharma's GxP World
- What You Should Know About USP's Bioassay Updates
- BlueRock Advances Cell Therapy For Parkinson's Disease
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
The Complete Flow Cytometry Guide
This guide covers the fundamentals of flow cytometry, aiming to help you better understand how it works, when it is most valuable, and how to conduct an experiment.
-
Transcriptome Profiling Of Cerebellar Organoids Grown In Dynamic Conditions
Learn about a method for generating human iPSC-derived cerebellar organoids that allows for the reproducible and large-scale production of organoids that recapitulate key features of cerebellar development.
-
In-Vivo CAR Therapies — Global Research And Development Landscape
Delve into the evolving in-vivo CAR therapy landscape, examining key technological innovations, major industry players, recent clinical progress, and regulatory developments.
-
Accelerating Bulk Harvest Testing Using A CHO Animal Origin Free Virus Panel
Here, we describe the design and performance of a degenerate PCR-based approach to broad virus screening that can be used in testing bulk harvest material derived from CHO cells.
-
Next-Generation CRISPR Approaches
By providing essential components like nucleases, gRNAs, and HDR templates, a reliable CDMO facilitates a seamless transition from discovery research to clinical trials and beyond.
-
Expert Insights In Navigating CGT's Complex Supply Chain
Examine insights shared during Cencora's ThinkLive Cell and Gene Therapy Summit 2024 that shed light on the challenges and opportunities in navigating the complexities of the cell and gene supply chain.
-
Automating High-Throughput Screens Using Patient-Derived Organoids
Many oncology drugs fail in later development stages due to inadequate predictive models. Explore how 3D cell models, like patient-derived organoids, offer a promising solution in the drug development process.
-
High-Throughput 90-Minute ELISA
Discover how one solution can be utilized to measure Human IgG and human IFN gamma, which are key targets in pharmacokinetic studies and immunotherapeutic drug safety testing, in just 90 minutes.
-
How Patient-Centric Approaches Are Shaping The Future Of CGT
Emily Whitehead’s CAR-T cell therapy journey highlights the power of patient engagement in cell and gene therapies. Discover how her story and advocacy drive a patient-centric approach in innovative treatments.
-
Automation Of iPSC Culture, Passaging, And Expansion
Find out how iPSC-derived models enable researchers to generate diverse cell types and tissues as well as how automation reduces the labor-intensive culturing process with AI-powered decision-making.
NEWSLETTER ARCHIVE
- 10.13.25 -- Exploring Biosafety And Quality Control In Lentiviral Vectors And CAR-T Therapies
- 10.13.25 -- On The Ground At BPI: Industry Reflections With Carl Schoellhammer, Ph.D.
- 10.11.25 -- Cell & Gene Best Of September
- 10.10.25 -- Advance Your Regulatory Submission With Expert Support And Tools
- 10.10.25 -- Inside Sanofi's Genomic Medicine Vision With Mike Quigley, Ph.D.

- Understanding CLL And SLL Treatment Evolution
- Advancing Telomere Targeting Therapy For Non-Small Cell Lung Cancer
- BlueRock Advances Cell Therapy For Parkinson's Disease
- Driving Prostate Cancer Innovation Through Immunotherapy With OS Therapies' Dr. Robert Petit
- The Future of Cancer Immunotherapy Through Allogeneic NK Cell Innovation
CELL AND GENE CONTENT COLLECTIONS

While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections